Viral Safety      

Viral safety of biologics such as human plasma proteins and recombinant therapeutics as well as vaccines for AIDS and other infectious diseases can be effected by utilizing a unique and broadly effective SuperFluids™ CFI virus inactivation technology [U.S. and International Patents].

SuperFluids™ are used to first permeate and inflate virions. The overfilled virions are then decompressed and, as a result of rapid phase conversion, rupture at their weakest points. CFI (critical fluid inactivation) of enveloped viruses such as MuLV, VSV, TGE, BDVD, Sindbis and HIV, and non-enveloped viruses such as Hepatitis A, Polio, Adeno, Reo, EMC and Parvovirus B19 has been demonstrated. The technique is purely physical and does not rely on heat, chemicals or irradiation, resulting in high retention of biological integrity and activity.

Aphios will license SuperFluids™ CFI for the viral safety of therapeutic proteins and pathogen inactivation, provide technical support as well as research and manufacturing units.  We will also develop commercial viral safety and pathogen inactivation relationships with strategic corporate partners.  

Aphios will further develop and license SuperFluids™ CFI for developing vaccines for AIDS and other infectious diseases [U.S. Patent].

Home l Company | Infectious Diseases | Oncology | Nutraceuticals | Product Pipeline | Purchase Products | Technology Platforms | Equipment |Patents | Press Releases | Contact Aphios